Biotechnology

Something Ventured

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

By Kate Sheridan

Biotech

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

By Adam Feuerstein

Biotech

Novartis ousted top scientists over manipulation of data for gene therapy

By Damian Garde and Matthew Herper

Biotech

Regeneron drug proves effective in genetic form of high cholesterol

By Matthew Herper and Damian Garde

Biotech

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

By Jonathan Saltzman — Boston Globe

Biotech

An old idea that’s gaining new traction: curing Alzheimer’s by targeting gum-disease bacteria

By Sharon Begley

Biotech

Toddler denied $2.1m gene therapy will now get it for free

By Jonathan Saltzman — Boston Globe

Adam's Take

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

By Adam Feuerstein

Biotech

Biotech faces a crisis in credibility fueled by boom-era hubris

By Matthew Herper

Senator Elizabeth Warren (D-MA) (L), Senator Bernie Sanders (I-VT) (2L), Senate Minority Leader Chuck Schumer (D-NY) (3L), Senator Tammy Baldwin (D-WI)

Politics

Senators blast Novartis over data manipulation before approval of Zolgensma

By Nicholas Florko

Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

The Readout LOUD

Listen: Novartis and the no good, very bad week

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

Sarepta’s stock price plummets after an ‘erroneous’ report

By Kate Sheridan

Health Tech

Health-tech startups dream of partnering with big drug makers. First comes an intense winnowing process

By Rebecca Robbins

Biotech

Novartis CEO: ‘We tried to do the right things’ in FDA data scandal

By Damian Garde

Biotech

‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different

By Kate Sheridan

Biotech

Novartis faces another crisis. And for CEO Vas Narasimhan, this time is different

By Damian Garde

Biotech

Novartis was aware of manipulation of data supporting gene therapy approval, FDA says

By Adam Feuerstein

Adam's Take

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

By Adam Feuerstein

Biotech

Alzheimer’s patients didn’t decline after getting a cocktail derived from young blood, but big questions remain

By Rebecca Robbins

Biotech

Blood test could replace biopsy for rare cancer treated by Keytruda

By Matthew Herper

Opinions Plus

How to create successful leadership teams for cell and gene therapy companies

By Nick Stephens

Biotech

Why biotech companies are often at the whim of things they cannot control, in one chart

By Damian Garde

Biotech

An expanded label for Amarin’s fish-oil drug looks more likely, but how fast will profits arrive?

By Adam Feuerstein

Biotech

Amgen’s KRAS-blocking cancer drug shows broader tumor-killing activity than previously reported

By Adam Feuerstein

Biotechnology

Is Roche starting a price war in cancer? Maybe not

How Amgen plans to BiTE into CAR-T’s hype

Roche drug approval offers a glimpse at the future of cancer treatment

Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

Novartis ousted top scientists over manipulation of data for gene therapy

Regeneron drug proves effective in genetic form of high cholesterol

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

An old idea that’s gaining new traction: curing Alzheimer’s by targeting gum-disease bacteria

Toddler denied $2.1m gene therapy will now get it for free

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

Biotech faces a crisis in credibility fueled by boom-era hubris

Senators blast Novartis over data manipulation before approval of Zolgensma

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

Listen: Novartis and the no good, very bad week

Sarepta’s stock price plummets after an ‘erroneous’ report

Health-tech startups dream of partnering with big drug makers. First comes an intense winnowing process

Novartis CEO: ‘We tried to do the right things’ in FDA data scandal

‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different

Novartis faces another crisis. And for CEO Vas Narasimhan, this time is different

Novartis was aware of manipulation of data supporting gene therapy approval, FDA says

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

Alzheimer’s patients didn’t decline after getting a cocktail derived from young blood, but big questions remain

Blood test could replace biopsy for rare cancer treated by Keytruda

How to create successful leadership teams for cell and gene therapy companies

Why biotech companies are often at the whim of things they cannot control, in one chart

An expanded label for Amarin’s fish-oil drug looks more likely, but how fast will profits arrive?

Amgen’s KRAS-blocking cancer drug shows broader tumor-killing activity than previously reported